AstraZeneca Harmonizes Listing Structure to Target Global Investor Base

AstraZeneca PLC (LON: AZN) has announced plans to harmonize its listing structure across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE).

The move, revealed in a release on Monday, aims to broaden the company’s access to global capital markets and enhance its appeal to a wider range of investors.

The core of the harmonization involves a direct listing of AstraZeneca ordinary shares on the NYSE. This will replace the existing American Depositary Receipts (ADRs) listed on Nasdaq.

The company emphasised that its headquarters, tax residency, and listing on the LSE and STO will remain unchanged, ensuring continued inclusion in the FTSE 100 and OMX Stockholm 30 indices.

Michel Demaré, Chair of AstraZeneca, stated: “Today we set out our proposed harmonised listing structure which will support our long-term strategy for sustainable growth, while remaining headquartered in the UK and listed in London, Stockholm and New York. Enabling a global listing structure will allow us to reach a broader mix of global investors and will make it even more attractive for all our shareholders to have the opportunity to participate in AstraZeneca’s exciting future.”